全文获取类型
收费全文 | 6356篇 |
免费 | 438篇 |
国内免费 | 28篇 |
专业分类
耳鼻咽喉 | 23篇 |
儿科学 | 346篇 |
妇产科学 | 60篇 |
基础医学 | 650篇 |
口腔科学 | 147篇 |
临床医学 | 772篇 |
内科学 | 1300篇 |
皮肤病学 | 63篇 |
神经病学 | 627篇 |
特种医学 | 729篇 |
外科学 | 580篇 |
综合类 | 87篇 |
一般理论 | 3篇 |
预防医学 | 557篇 |
眼科学 | 265篇 |
药学 | 358篇 |
1篇 | |
中国医学 | 1篇 |
肿瘤学 | 253篇 |
出版年
2021年 | 74篇 |
2020年 | 47篇 |
2019年 | 64篇 |
2018年 | 95篇 |
2017年 | 63篇 |
2016年 | 94篇 |
2015年 | 78篇 |
2014年 | 100篇 |
2013年 | 159篇 |
2012年 | 179篇 |
2011年 | 193篇 |
2010年 | 164篇 |
2009年 | 175篇 |
2008年 | 210篇 |
2007年 | 225篇 |
2006年 | 226篇 |
2005年 | 203篇 |
2004年 | 216篇 |
2003年 | 192篇 |
2002年 | 188篇 |
2001年 | 180篇 |
2000年 | 177篇 |
1999年 | 156篇 |
1998年 | 149篇 |
1997年 | 150篇 |
1996年 | 160篇 |
1995年 | 113篇 |
1994年 | 117篇 |
1993年 | 128篇 |
1992年 | 128篇 |
1991年 | 130篇 |
1990年 | 142篇 |
1989年 | 170篇 |
1988年 | 159篇 |
1987年 | 157篇 |
1986年 | 183篇 |
1985年 | 158篇 |
1984年 | 100篇 |
1983年 | 104篇 |
1982年 | 80篇 |
1981年 | 86篇 |
1980年 | 72篇 |
1979年 | 103篇 |
1978年 | 84篇 |
1977年 | 83篇 |
1976年 | 68篇 |
1975年 | 52篇 |
1974年 | 55篇 |
1973年 | 52篇 |
1970年 | 44篇 |
排序方式: 共有6822条查询结果,搜索用时 15 毫秒
81.
82.
83.
Vaughan JR; Farrer MJ; Wszolek ZK; Gasser T; Durr A; Agid Y; Bonifati V; DeMichele G; Volpe G; Lincoln S; Breteler M; Meco G; Brice A; Marsden CD; Hardy J; Wood NW 《Human molecular genetics》1998,7(4):751-753
A mutation in exon 4 of the human alpha-synuclein gene was reported
recently in four families with autosomal dominant Parkinson's disease (PD).
In order to examine whether mutations in this exon or elsewhere in the gene
are common in familial PD, all seven exons of the alpha- synuclein gene
were amplified by PCR from index cases of 30 European and American
Caucasian kindreds affected with autosomal dominant PD. Each product was
sequenced directly and examined for mutations in the open reading frame. No
mutations were found in any of the samples examined. We conclude that the
A53T change described in the alpha- synuclein gene is a rare cause of PD or
may even be a rare variant. Mutations in the regulatory or intronic regions
of the gene were not excluded by this study.
相似文献
84.
Distribution of mutations in the PEX gene in families with X-linked hypophosphataemic rickets (HYP) 总被引:8,自引:0,他引:8
Rowe PS; Oudet CL; Francis F; Sinding C; Pannetier S; Econs MJ; Strom TM; Meitinger T; Garabedian M; David A; Macher MA; Questiaux E; Popowska E; Pronicka E; Read AP; Mokrzycki A; Glorieux FH; Drezner MK; Hanauer A; Lehrach H; Goulding JN; O'Riordan JL 《Human molecular genetics》1997,6(4):539-549
Mutations in the PEX gene at Xp22.1 (phosphate-regulating gene with
homologies to endopeptidases, on the X-chromosome), are responsible for
X-linked hypophosphataemic rickets (HYP). Homology of PEX to the M13 family
of Zn2+ metallopeptidases which include neprilysin (NEP) as prototype, has
raised important questions regarding PEX function at the molecular level.
The aim of this study was to analyse 99 HYP families for PEX gene
mutations, and to correlate predicted changes in the protein structure with
Zn2+ metallopeptidase gene function. Primers flanking 22 characterised
exons were used to amplify DNA by PCR, and SSCP was then used to screen for
mutations. Deletions, insertions, nonsense mutations, stop codons and
splice mutations occurred in 83% of families screened for in all 22 exons,
and 51% of a separate set of families screened in 17 PEX gene exons.
Missense mutations in four regions of the gene were informative regarding
function, with one mutation in the Zn2+-binding site predicted to alter
substrate enzyme interaction and catalysis. Computer analysis of the
remaining mutations predicted changes in secondary structure,
N-glycosylation, protein phosphorylation and catalytic site molecular
structure. The wide range of mutations that align with regions required for
protease activity in NEP suggests that PEX also functions as a protease,
and may act by processing factor(s) involved in bone mineral metabolism.
相似文献
85.
Identification of the multiple endocrine neoplasia type 1 (MEN1) gene. The European Consortium on MEN1 总被引:10,自引:0,他引:10
Lemmens I; Van de Ven WJ; Kas K; Zhang CX; Giraud S; Wautot V; Buisson N; De Witte K; Salandre J; Lenoir G; Pugeat M; Calender A; Parente F; Quincey D; Gaudray P; De Wit MJ; Lips CJ; Hoppener JW; Khodaei S; Grant AL; Weber G; Kytola S; Teh BT; Farnebo F; Thakker RV 《Human molecular genetics》1997,6(7):1177-1183
86.
P. H. Wooley J. D. Whalen J. L. Zimmerman T. M. Champion 《Inflammation research》1987,21(3-4):244-246
Type II collagen-induced arthritis (CIA) and mice was used as a model to evaluate the effect of etodolac on the arthritic and immunological parameters of the experimental disease. In a preventative protocol, a significant reduction was observed in the number of joints progressing to ankylosis. At high doses (16 mg/kg/day) a significant delay in the onset of arthritis was also observed. No significant effect was seen on the progression of the disease when etodolac was administered in established CIA. No consistent variations were observed in the anti-type II collagen response or other immunological parameters of the experimental arthritis. 相似文献
87.
Rigor and resistance to stretch in vertebrate smooth muscle 总被引:2,自引:0,他引:2
88.
A prospective trial of colchicine for primary biliary cirrhosis 总被引:10,自引:0,他引:10
M M Kaplan D W Alling H J Zimmerman H J Wolfe R A Sepersky G S Hirsch G H Elta K A Glick K A Eagen 《The New England journal of medicine》1986,315(23):1448-1454
We entered 60 patients with primary biliary cirrhosis in a double-blind randomized controlled trial to determine whether colchicine is therapeutically effective. Thirty patients had early disease (Stages 1 and 2), and 30 had advanced disease (Stages 3 and 4). Fifteen patients with early disease and 15 with advanced disease received colchicine (0.6 mg twice daily), and the remainder received placebo. Patients were studied about every two months; those remaining in the blind phase at two years underwent repeat liver biopsy and were then placed on open-label colchicine (0.6 mg twice daily). With a few exceptions, the results in patients with early disease were similar to those in patients with advanced disease; hence, data on patients in all stages were combined in the main analysis. During the two-year study period the colchicine-treated patients, as compared with the placebo-treated patients, had improvement in levels of serum albumin, serum bilirubin, alkaline phosphatase, cholesterol, and aminotransferases. However, there was no such improvement in the severity of symptoms or physical findings; moreover, there was no significant difference in the histologic changes noted at liver biopsy in the two treatment groups. At four years after entry, the cumulative mortality from liver disease was 21 percent in patients given colchicine and 47 percent in those given placebo (P = 0.05). The only side effect of colchicine was diarrhea, noted in three patients. The consistent and significant improvement in a number of markers of liver disease and the apparent decreased mortality from liver disease suggest that colchicine may provide some long-term clinical benefit in patients with primary biliary cirrhosis. However, the failure of colchicine to reduce hepatic inflammation and fibrosis leaves uncertain the effect of the drug on the longterm outcome of this disease. 相似文献
89.
Billette J; Janse MJ; van Capelle FJ; Anderson RH; Touboul P; Durrer D 《The American journal of physiology》1976,231(4):1129-1139
90.